Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
55 Network Drive
Burlington, MA 01803
United States of America
Dyax's mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs while delivering outstanding value to patients and stockholders. At the core of our success is our powerful and proprietary drug discovery technology, phage display. This technology provides us a unique advantage of being able to identify and develop our own clinical leads to fuel our internal pipeline. We also leverage phage display into licenses and collaborations with companies and researchers interested in furthering their own pipelines.
Ecallantide (trade name: Kalbitor), from Dyax Corp., is a recombinant product that inhibits kallikrein - an enzyme that plays a key role in the biochemical processes that lead to HAE-related swelling.
The product is delivered through subcutaneous injections and is approved for the treatment of acute HAE attacks in December 2009 by the FDA for the US market.
Dyax is currently working - also with partners - to make Kalbitor available in other parts of the world.